|
SAMe
(S-Adenosyl Methionine)
Is manufactured in the body but also made synthetically.
SAMe alleviates all forms of Depression [many studies have confirmed that SAMe is more effective (approximately 15%) in the treatment of depression than antidepressants].
SAMe is especially effective in treating postpartum Depression.
SAMe counteracts the anxiety and depression commonly experienced by persons with drug dependence during detoxification [1,200 mg of SAMe per day significantly reduced the psychological stress encountered by former opiate users during their detoxification period].
AIDS patients have low cerebrospinal fluid levels of SAMe and for this reason SAMe is under investigation as a potential treatment for
AIDS.
SAMe helps to protect against liver cancer in persons exposed to Liver carcinogens.
SAMe inhibits Alcohol-induced Liver damage. SAMe can prevent and cure
cirrhosis.
SAMe (800 mg per day) alleviates Fibromyalgia [800 mg of SAMe per day had a significant reduction in the number of trigger points, reduction in fatigue, reduction in morning stiffness, and improvements in mood in Fibromyalgia patients].
SAMe improves Osteoarthritis.
Alzheimer's patients have severely decreased levels of SAMe within their brains.
SAMe is presently under investigation as a potential treatment for Parkinson's [Parkinson's patients have levels of SAMe that are only 60% of the levels of those of healthy subjects].
SAMe improves the ability of Neurotransmitters to bind to their receptor sites.
SAMe is an essential cofactor for the conversion of Norepinephrine to Adrenaline.
References
SAMe
article
Bell, K. M., et al. S-adenosylmethionine treatment of depression: A controlled clinical trial. American Journal of Psychiatry. 145:1110-1114, 1988.
De Vanna, M., et al. Oral S-adenosyl-methionine in depression. Curr Ther Res. 52:478-485, 1992
Vahora, S. A., et al. S- adenosyl-methionine in depression. Neurosci Biobehav Rev. 12:139-141, 1988
Tavoni, A., et al. Evaluation of S-adenosylmethionine in primary fibromyalgia. Am. J. Med. 83 (Supplement 5A):107-110, 1987.
G. Stramentinoli (1987) "Pharmacologic aspects of [SAMe]" Am J Med 83 (suppl 5A), 35-42.
L. Morrison et al, (1996) "Brain [SAMe] levels are severely decreased in Alzheimer's disease"
J Neurochem 67, 1328-31.
C. di Padova (1987) "[SAMe] in the treatment of osteoarthritis" Am J Med 83 (suppl 5A), 60-65.
B Konig (1987) "A long term (2 years) clinical trail with [SAMe] for the treatment of osteoarthritis" Am J Med 83, (suppl 5A), 89-94.
G. Vendemiale et al, (1989) "Effects of oral [SAMe] on hepatic glutathione.. liver disease" Scand J Gastroent 24, 407-14.
E. Reynolds et al, (1984) "Methylation and mood" Lancet II, 196-98.
L. Bonanomi & A. Gazzaniga (1980) "Toxicological, Pharmacokinetic and Metabolic Studies on Acetylcysteine" Eur J Repir Dis 61, 45-51.
A. Tavoni et al, (1987), "Evaluation of [SAMe] in Primary Fibromyalgia" Am J Med *3 (sippl 5A), 107-110.
K. McCully, The Homocysteine Revolution, New Canaan CT; Keats (1997).
O. Laudonno (1987) "Cytoprotective effect of [SAMe] compared with... Misoprostol against... gastric damage" Am J Med 83 (suppl 5A), 43-47.
I. Caruso & V. Pietrogrande (1987) " Comparing [SAMe], Naproxen and placebo in the treatment of degenerative joint disease" Am J Med 83 (suppl 5A), 66-71.
M. Frezza et al, (1988) "Prevention by [SAMe] of estrogen induced hepatobiliary toxicity in... women" Am J Gastroent 83, 1098-1102.
G. Vendemiale et al, (1989) "Effects of oral [SAMe] on hepatic glutathione.. liver disease" Scand J Gastroent 24, 407-14.
F. Corrales et al, (1991) "Inhibition of glutathione synthesis in the liver leads to [SAMe] synthetase reduction" Hepatol 14, 528-33.
B. Kagan et al, (1990) "Oral [SAMe] in depression: a... double-blind, placebo controlled trial" Am J Psychiat 147, 591-95.
C. Mathews & K. van Holde, Biochemistry, pp. 708-715, Redwood City, CA: Benjamin/ Cummings Pub. Co. (1990).
|
